Welcome to our dedicated page for Astera Labs SEC filings (Ticker: ALAB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Astera Labs's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Astera Labs's regulatory disclosures and financial reporting.
A Form 144 filing for Astera Labs indicates a proposed sale of 686 shares of common stock with an aggregate market value of $60,368. The sale is planned to be executed through UBS Financial Services on the NASDAQ exchange, with an approximate sale date of June 24, 2025.
The shares were acquired on June 23, 2025, through a Restricted Stock Unit (RSU) grant from the issuer. The current total shares outstanding for the company is 164,916,814.
Key details:
- Share price implied by filing: ~$88 per share
- Transaction represents approximately 0.0004% of total shares outstanding
- No other securities were sold by the filer during the past 3 months
- Sale will be executed on NASDAQ through UBS Financial Services
Astera Labs President and COO Sanjay Gajendra executed multiple stock sales on June 18, 2025, through a pre-planned Rule 10b5-1 trading arrangement established on November 30, 2024. The transactions included:
- 52,933 shares sold at weighted average price of $98.3779
- 4,926 shares sold at weighted average price of $99.2065
- Two separate sales of 9,257 shares each at approximately $98.19 per share
Following these transactions, Gajendra's beneficial ownership stands at:
- 2,262,318 shares held directly
- 5,930,545 shares in Trust 1
- 715,000 shares each in Trust 2 and Trust 3
The sales were executed automatically under the trading plan, demonstrating structured portfolio management by the insider. Gajendra maintains significant ownership through both direct holdings and trust arrangements, while disclaiming beneficial ownership of trust-held shares except for his pecuniary interest.
Jitendra Mohan, Chief Executive Officer and Director of Astera Labs (ALAB), reported multiple sales of common stock on June 17, 2025, executed through a pre-established Rule 10b5-1 trading plan from December 2, 2024.
The transactions involved the sale of 106,510 total shares at a weighted average price of $94.5417 per share across six different trusts. The sales were executed in multiple tranches with prices ranging from $93.36 to $96.78 per share.
Following the transactions, Mohan's holdings are distributed as follows:
- Direct ownership: 2,262,318 shares
- Indirect ownership through various trusts: - Living Trust: 4,351,010 shares - Trust: 771,003 shares - 2021 Trusts: 1,542,014 shares combined - 2022 Trusts: 1,042,016 shares combined
The filing indicates Mohan disclaims beneficial ownership of the trust-held securities except for his pecuniary interest.
Astera Labs, Inc. (ALAB) filed a Form S-8 on 18 June 2025 to register 9,721,048 additional shares of common stock for issuance under two employee equity programs:
- 2024 Stock Option & Incentive Plan: 8,100,874 shares
- 2024 Employee Stock Purchase Plan: 1,620,174 shares